MedTrace Logo

A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity

NCT03509922 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-06-23

No results posted yet for this study

Summary

This study is to evaluate the effect of sarpogrelate on blood viscosity after 24 weeks in patients with high blood viscosity.

Conditions

  • Peripheral Artery Disease, PAD

Interventions

DRUG

Anplag Tab. 100mg bid

sarpogrelate hydrochloride 100mg bid for 24 weeks

DRUG

Anplag Tab. 100mg tid

sarpogrelate hydrochloride 100mg tid for 24 weeks

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-11
Primary Completion
2019-12-26
Completion
2020-03-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03509922 on ClinicalTrials.gov